drug

PN-881

1 story · latest Aug 5, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Protagonist Therapeutics, Inc.

Timeline

Protagonist posts Q2 2026 profit as ICOTYDE launch and rusfertide review advance

Aug 5Quarterly updateicotrokinra Johnson & Johnson

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.